跳至主要内容
临床试验/SLCTR/2021/024
SLCTR/2021/024尚未招募2 期

Efficacy of nebulised Homo-Harringtonine (HHT) on the clearance of the viral load in patients with SARS-CoV-2 who are under care of intermediate care centre at Arachchikanda, Galle ; A randomised placebo controlled double-blind clinical trial

Mr Jian Li0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Previously healthy adult volunteers between the age of 30 to 60 years
  • 2. Both male and female
  • 2.Positive PCR for SARS – Cov 2 (COVID-19) with a CT value of less than 25
  • 3.With no or mild symptoms of COVID-19 such as fever, rhinorrhoea, anosmia and sore throat

排除标准

  • 1.Known or suspected allergy to drugs
  • 2.According to the current trial implementation of the latest version of the New Coronavirus Infection Pneumonia Diagnosis and Treatment Plan, the patient is diagnosed as a critically ill patient with novel coronavirus pneumonia;
  • 3.Combined with severe liver disease (Total bilirubin:TBIL >=2 ULN, alanine transaminase; ALT, aspartate transaminase; AST >=5 ULN (Abnormalities in these liver enzymes are generally considered mild if <5 times the ULN, moderate if 5-10 times the ULN or marked if >10 times the ULN)
  • 4.Patients with severe renal insufficiency (glomerular filtration rate <=60 mL/min/1.73m2) or who are receiving continuous renal replacement therapy, hemodialysis, and peritoneal dialysis;
  • 5.Patients who have severe breathing difficulties and cannot complete the self-aerosolized drug inhalation;
  • 6.Patients with hematological tumors;
  • 7.Patients who have used antiviral drugs in the past 2 months, such as interferon, lopinavir, ritonavir, remdesivir, etc.,or are receiving other antiviral drugs;
  • 8.Women who are pregnant or breastfeeding or have a birth plan during the trial period and within 6 months after the end of the trial;
  • 9.Are participating in other clinical trials or are using experimental drugs;
  • 10.Rehabilitation plasma therapy for patients with COVID-19;
  • 11.Are using Aurvedic medicine for treatment;
  • 12.Patients with diabetes, hypertension and obese people;
  • 13.According to the judgment of the research team, there are other circumstances that are not suitable for participating in this trial. Eg; Geographical distance for the research centre for follow up subjects.
  • 14. Vulnerable people Eg; Prisoners

研究者

发起方
Mr Jian Li

相似试验

Efficacy of nebulized Homo-Harringtonine (HHT)... | 临床试验